Quidel Corporation (“Quidel”), a subsidiary of QuidelOrtho Corporation (NASDAQ: QDEL) and a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and the World Champion Los Angeles Rams today announced a multi-year partnership agreement to promote health awareness and COVID-19 testing. The agreement makes Quidel an “Official Partner of the Los Angeles Rams” and designates Quidel’s QuickVue at-home rapid antigen test as the “Official At-Home COVID Test of the Los Angeles Rams.” In addition, the partnership includes a variety of promotions and stadium activation initiatives as well as a presence at community programs across the greater Los Angeles area.
"As a leading diagnostics company founded and headquartered in Southern California, Quidel is proud to be an official partner of the Los Angeles Rams," said Douglas Bryant, Chairman and CEO of QuidelOrtho. "It is an honor to work close to home and with a winning organization whose dedication to community service matches our own. We look forward to teaming up to promote health awareness and the benefits of COVID-19 testing."
“As we prepare to kick off our season and defend our championship, we are pleased to welcome Quidel to the Rams family,” said Rams Chief Commercial Officer Jen Prince. “Quidel’s history in Southern California and commitment to health and wellness make them a great fit to help enhance gamedays and our community events year-round.”
Mr. Bryant noted, “With our 10-minute QuickVue rapid antigen test taking the field as the ‘Official At-Home COVID Test of the Los Angeles Rams,’ we will work with the Rams organization to champion the message of easy and accessible at-home COVID-19 testing at the stadium and further communicate the importance of testing to all communities through Rams radio, television, and digital programming.”
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) unites the power of Quidel Corporation and Ortho Clinical Diagnostics behind a shared mission of developing and manufacturing innovative technologies that raise the performance of diagnostic testing and create better patient outcomes across the entire healthcare continuum.
Ranked among the world’s largest in vitro diagnostics (IVD) providers with more than 120 years of collective experience, we combine industry-leading expertise in immunoassay and molecular testing with a global footprint in clinical labs and transfusion medicine.
Our company’s comprehensive product portfolio delivers accuracy, speed, automation and access, providing critical information when and where it is needed most. Inspired by a spirit of service, the QuidelOrtho family is committed to enhancing the well-being of people worldwide and happy in the knowledge we are making a difference. For more information, please visit www.quidelortho.com.